[TOP STORY] The appetite for GLP-1 drugs grows

Loading player...
‘The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, Integral Asset Management’s Keith McLachlan points out.
24 Jan 2025 3AM English South Africa Business News · Business

Other recent episodes

Nvidia: What now?

A look at Nvidia and which South African consumer stocks could benefit from a recovery in discretionary spending. Plus, what upcoming credit rating reviews could mean for SA’s markets.
13 Nov 12AM 22 min